Valuation
- Market cap
- 531,902,000
- Revenue TTM
- $10,840,000
- Net income TTM
- $-153,940,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,420.11%
- Debt to equity
- 0.00
Trading
- Volume
- 283,200
- Avg volume
- 359,026
- Day's range
- $14.07 – $14.55
- Shares out
- 37,144,000
- Stochastic %K
- 27%
- Beta
- 1.27
- Analysts
- Strong Sell
- Price target
- $31.33
Company profile
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commerciali...
Show more
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 460 5595
- Website
- https://crescentbiopharma.com
- Address
- 300 Fifth Avenue, Waltham, United States
Latest news
No headlines yet.
